Histopathology · 2003 · 180 citations · 34 references
MedicineOncologyCancer GeneticsMolecular OncologyNeoplasiaMalignant Parotid TumorsMalignant Salivary Gland TumorsSalivary Gland PathologySalivary GlandsImmunohistochemistry Of Salivary GlandsMalignant Salivary Gland NeoplasmsParotid Gland CarcinomaParotid Gland Histology
AIMS: Salivary duct carcinoma is a highly malignant salivary gland tumour with aggressive clinical behaviour, characterized by histological resemblance to invasive ductal carcinoma of the breast. Amplification of HER-2/neu oncogene and over-expression of its gene product have both prognostic and therapeutic implications in breast cancer. Recent report on salivary duct carcinomas for HER-2/neu using immunohistochemistry (IHC) has shown over-expression in most cases. However, correlation between IHC and molecular genetic analysis of HER-2/neu in salivary duct carcinoma has not yet been performed. METHODS AND RESULTS: We have now evaluated 11 cases of salivary duct carcinomas for HER-2/neu status using IHC and fluorescent in-situ hybridization (FISH). To our knowledge, this is the first molecular genetic analysis of HER-2/neu in salivary duct carcinoma. CONCLUSIONS: In immunohistochemistry, over-expression of HER-2/neu protein was identified as distinct membrane staining in most carcinoma cells in all our salivary duct carcinoma cases, while only four cases revealed an amplification of HER-2/neu gene by means of FISH analysis. Both amplified and non-amplified salivary duct carcinomas with strong immunohistochemical staining for HER-2/neu protein were associated with poor clinical outcome for the patients. Apparently, HER-2/neu protein over-expression could also be controlled by mechanisms other than gene amplification. In the group of salivary gland tumours other than salivary duct carcinoma, strong over-expression was detected only in three cases of carcinoma ex pleomorphic adenoma. Thus, over-expression of HER-2/neu protein is also a useful marker of malignant transformation in pleomorphic adenomas.
34
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Mark D. Pegram, A. Lipton, Daniel F. Hayes et al. · Journal of Clinical Oncology · 1998 · 1.1K citations
Medicine, Oncology, Pharmacology +17
Timothy W. Jacobs, Allen M. Gown, Hadi Yaziji et al. · Journal of Clinical Oncology · 1999 · 459 citations · Full text